The sickle-cell trait modifies the intensity and specificity of the immune response against P. falciparum malaria and leads to acquired protective immunity.
It is proposed that the in vivo mechanism of protection against falciparum malaria in individuals of the Hb AS genotype is not due solely to the adverse influence of Hb AS erythrocytes on the intraerythrocytic growth and development of P. falciparum. Instead, the simple physiological effect of Hb S on parasite growth appears to trigger an in vivo process of enhancement of the intensity and/or specificity of the host immune response, leading to acquired protective immunity, in a process simulating vaccination. Testing the hypothesis may lead to the identification of plasmodial antigens that induce protective responses in the human host and distinguish them from non-protective, immunosuppressive or decoy antigens that promote parasite survival. This may ultimately help in the selection of candidate antigens for a malaria blood-stage vaccine.
Bayoumi
R A
RA
D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications / Q000276:immunology* / Q000469:parasitology; D000917:Antibody Formation; D000918:Antibody Specificity; D002531:Cerebellum / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D006451:Hemoglobin, Sickle / Q000502:physiology; D006801:Humans; D007223:Infant; D008288:Malaria / Q000150:complications / Q000276:immunology*; D010963:Plasmodium falciparum / Q000254:growth & development / Q000276:immunology; D013154:Spleen / Q000473:pathology
D006451:Hemoglobin, Sickle